Furthermore, second-generation EGFR-TKIs constitute first-line treatment alternatives for EGFR-mutated advanced NSCLC because no phase III clinical trial has compared the clinical efficacy of second-generation EGFR-TKIs and osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.